Journal
Future Oncology
Publication Date
3-1-2023
Volume
19
Issue
8
First Page
559
Last Page
573
Document Type
Open Access Publication
DOI
10.2217/fon-2022-1196
Rights and Permissions
Turner N, Huang-Bartlett C, Kalinsky K, Cristofanilli M, Bianchini G, Chia S, Iwata H, Janni W, Ma CX, Mayer EL, Park YH, Fox S, Liu X, McClain S, Bidard FC. Design of SERENA-6, a phase III switching trial of camizestrant in ESR1-mutant breast cancer during first-line treatment. Future Oncol. 2023 Mar;19(8):559-573. doi: 10.2217/fon-2022-1196. This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/. For full bibliographic citation, please refer to the version available at www.futuremedicine.com.
Recommended Citation
Turner, Nicholas; Huang-Bartlett, Cynthia; Kalinsky, Kevin; Cristofanilli, Massimo; Bianchini, Giampaolo; Chia, Stephen; Iwata, Hiroji; Janni, Wolfgang; Ma, Cynthia X; Mayer, Erica L; Park, Yeon Hee; Fox, Steven; Liu, Xiaochun; McClain, Sasha; and Bidard, Francois-Clement, "Design of SERENA-6, a phase III switching trial of camizestrant in ESR1-mutant breast cancer during first-line treatment." Future Oncology. 19, 8. 559 - 573. (2023).
https://digitalcommons.wustl.edu/oa_4/1630
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
